Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06. The security is pacing for its worst single-day percentage loss since October 2023 after the gene-editing company revealed a 16-year-old boy died from acute liver failure after receiving its gene therapy for a rare muscular dystrophy. Year to date, the equity is down 37.5%. Beam Therapeutics Inc (NASDAQ:BEAM) is down 6.8% to trade at $22.85 at last glance, brushing off a price-targ ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

On Tuesday, Sarepta Therapeutics, Inc. SRPT stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.The company reported a patient death following treatment with Elevidys, having suffered acute liver failure.Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.Also Read: Solid Biosciences Outpaces ...

I've been writing for Seeking Alpha since 2017 with a focus on healthcare and technology investments. With a background as a Registered Nurse, I analyze biotech stocks by evaluating clinical data, treatment guidelines, and market dynamics. My MBA provided a foundation of financial theory, allowing me to expand into technology investments, where I focus on identifying key valuation drivers and using DCF modeling for scenario-based forecasts. My thinking is influenced by books such as "Superforecasting" and " ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdi ...

Sarepta Therapeutics, Inc. (SRPT) reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks Consensus Estimate of $1.87. However, the reported figure was significantly higher than the year-ago period’s 47 cents due to higher product sales.The loss included depreciation and amortization costs and stock-based compensation expenses. The adjusted EPS in the quarter was $1.90 compared with 82 cents in the year-ago period.Sarepta recorded total revenues of $658.4 million, up 66% year ...

Financial Data and Key Metrics Changes - For Q4 2024, the company reported total revenues of $658.4 million, an increase of $261.6 million compared to $396.8 million in Q4 2023 [64] - Net product revenue for Q4 2024 was $638 million, growing 75% year-over-year, and full-year net product revenue reached $1.8 billion, representing a 56% increase [14][64] - The company achieved a GAAP net income of $159 million for Q4 2024, compared to $45.7 million in Q4 2023, and a non-GAAP net income of $206 million, up from $86.6 million [66] Business Line Data and Key Metrics Changes - ELEVIDYS sales for Q4 2024 were $384.2 million, a 112% increase from the previous quarter, and total sales since its launch exceeded $1 billion [15][28] - The PMO franchise generated $254 million in Q4 2024, growing approximately 9% compared to Q4 2023, with individual revenues of $137.6 million for EXONDYS 51, $40.2 million for VYONDYS 53, and $76.2 million for AMONDYS 45 [31][32] Market Data and Key Metrics Changes - The company noted that ELEVIDYS has only treated about 5% of the on-label addressable patient population, indicating significant growth potential ahead [33][41] - The PMO franchise continues to perform well, growing organically without price increases, reflecting an increase in patients served in the Duchenne community [30] Company Strategy and Development Direction - The company aims to build on the success of Project Moonshot, focusing on expanding its gene therapy pipeline and achieving multiple potential blockbuster siRNA launches by the end of the decade [9][13] - The strategic collaboration with Arrowhead is expected to diversify the company's future, adding a broad platform of siRNA programs across various diseases [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2025 net product revenue guidance of $2.9 billion to $3.1 billion, representing a 70% year-over-year growth [17][42] - The company anticipates continued quarter-over-quarter growth throughout 2025, driven by strong demand for ELEVIDYS and the PMO franchise [81] Other Important Information - The company plans to transition to suspension manufacturing to improve cost of goods sold (COGS) and is preparing for multiple upcoming clinical milestones in 2025 [20][21] - The company has approximately $1.5 billion in cash and investments as of December 31, 2024, and secured a $600 million revolving credit facility to support its strategic goals [71][72] Q&A Session Summary Question: What is the cadence of patient onboarding in Q1? - Management reiterated confidence in guidance for 2025, expecting growth quarter-over-quarter as the launch ramps up [80] Question: What is the prevalence of limb-girdle muscular dystrophy type 2E? - Management indicated that type 2E is an ultra-rare disease, with a 50-50 split between ambulatory and non-ambulatory patients [85][87] Question: Will the upcoming data for FSHD and DM1 be conclusive? - Management stated that the initial single ascending dose (SAD) data will provide important proof of biology, but further data will be needed for definitive conclusions [108][110] Question: What is the status of reimbursement for PMOs in ELEVIDYS treated patients? - Management noted early signs of reimbursement for both therapies, but emphasized that it is still early days to draw broad conclusions [115][117] Question: What is the timeframe for the $500 million share repurchase program? - The program has an 18-month timeframe, and management plans to be opportunistic in deploying capital as cash reserves are built back up [125][126]

Patients can't wait for the next breakthrough in medical research. So neither will we. Fourth Quarter and Full Year 2024 Financial Results Wednesday, February 26, 2025 MELANIE Living with limb-girdle muscular dystrophy ©SAREPTA THERAPEUTICS, INC. 2025. ALL RIGHTS RESERVED. 1 Forward Looking Statements In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta th ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Doug Ingram - President and CEO Ian Estepan - Executive Vice President and CFO Dallan Murray - Executive Vice President and CCO Dr. Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head, Research & Development Conference Call Participants Tazeen Ahmad - Bank of America Securi ...

Core Viewpoint - Sarepta Therapeutics reported quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share, representing an earnings surprise of -19.79% [1] - The company posted revenues of $658.41 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.83% and showing a significant increase from $396.78 million year-over-year [2] Financial Performance - Earnings per share (EPS) for the current quarter was $1.50, compared to $0.47 per share a year ago [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $1.73, with expected revenues of $656.12 million, and for the current fiscal year, the EPS estimate is $10.94 on revenues of $3.03 billion [7] Market Performance - Sarepta Therapeutics shares have declined approximately 12% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's Zacks Rank is currently 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry is currently in the top 24% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]